November 2011 - Che-courtesy-list

Delete email "Reset Your Account"
by Harrington, Michael P 08 Nov '11

08 Nov '11

Several people have received an email stating to "Reset your Account" - It at the very least spam and may be a phishing email. Please delete it. -Mike Harrington ******************** Mike Harrington Computer Facilities Manager Chemical Engineering Purdue University 765-494-6428 mph(a)purdue.edu

1 0

KEYS LEFT IN 2107 ---- THEY ARE IN THE MAIN OFFICE --- 1060
by Heide, Karen Kay 07 Nov '11

07 Nov '11

The office will close at 5 pm today. Karen Mrs. Karen Heide, Secretary School of Chemical Engineering Purdue University Forney Hall of Chemical Engineering 480 Stadium Mall Drive West Lafayette IN 47907-2100 765-494-4050 765-494-0805 (Fax)

1 0

Network and Computer issues
by Harrington, Michael P 04 Nov '11

04 Nov '11

Hi, We've been experiencing issues with atom and / or the network connection to atom over the last two days. You may have seen this manifest itself with "Delayed write failures" in windows, slowness when sending or manipulating emails especially if you use ECN's mail system (as opposed to exchange/outlook), and general slowness when using any ECN deployed machine or connecting to atom from a non-ecn deployed machine. I have been in contact with ECN since yesterday on this issue - things seem to clear up late Thursday afternoon but it also appears the issues have now started again late this morning. ECN is looking into the issue and I will send out an update when I have any additional information. I'm sorry for the inconveniences this is causing and please know I am experiencing the same issues myself. Mike ******************** Mike Harrington Computer Facilities Manager Chemical Engineering Purdue University 765-494-6428 mph(a)purdue.edu

1 0

FW: Remember, Campus Sirens Replaced, to be Tested Today
by Valley, Jeffrey L 04 Nov '11

04 Nov '11

FYI......................... From: Terry, Rebecca L [mailto:rlterry@purdue.edu] Sent: Friday, November 04, 2011 8:26 AM Subject: Remember, Campus Sirens Replaced, to be Tested Today Communications Announcement Purdue University - Physical Facilities TO: Building Deputies (Please distribute) FR: Campus Emergency Preparedness and Planning Office DA: Friday, November 4, 2011 RE: Remember, Campus Sirens Replaced, to be Tested Today Purdue University has replaced all of its all-hazards outdoor warning sirens and added two new ones on campus. A test of the system will be conducted between 1-4 p.m. Friday, November 4. The university has sirens at Earhart Hall, Hawkins Hall, the Heine Pharmacy Building, Purdue Village, Hilltop Apartments, the Grand Prix race track and the Physical Facilities Service Building. Friday's test is to ensure the sirens are operable and will include an activation of sirens that could last up to 30 seconds and may be noticeable on campus. However, the potential for a full, three-minute siren activation is possible. Siren system checkout and verification may require multiple tests during the time frame. If there is inclement weather, the test will be cancelled. Please disregard any siren activation during this time period; no action is necessary. If you have any questions, please contact the Emergency Preparedness Office at 4-0446.

1 0

FW: US 52 Project Will Shift Traffic Late Friday; Sidewalk Closure on North Side of Cary Begins Monday
by Valley, Jeffrey L 03 Nov '11

03 Nov '11

FYI....................... From: Terry, Rebecca L [mailto:rlterry@purdue.edu] Sent: Thursday, November 03, 2011 3:42 PM Subject: US 52 Project Will Shift Traffic Late Friday; Sidewalk Closure on North Side of Cary Begins Monday Communications Announcement Purdue University - Physical Facilities TO: Building Deputies (Please distribute) FR: Physical Facilities DA: Thursday, November 3, 2011 RE: US 52 Project Will Shift Traffic Late Friday; Sidewalk Closure on North Side of Cary Begins Monday US 52 Project Will Shift Traffic Late Friday The Indiana Department of Transportation (INDOT) announce US 52 eastbound traffic will be shifted into the newly constructed eastbound lanes and leave westbound traffic in the westbound lanes by late Friday afternoon. Crews with Walsh Construction Co. have nearly completed the reconstruction of US 52 between Schuyler Ave. and Greenbush. There will only be daytime lane restrictions in the area in which they will be working until the contractor finishes up work in the next couple of weeks. Motorists are encouraged to be aware of the changes in traffic patterns. Other improvements as part of the reconstruction will include shoulder, curbs and gutters, drainage structures, culvert, guardrail, and sign replacement. The turn lanes will be lengthened at the intersection of Underwood and O'Farrell Streets. This project is scheduled to be completed in August of 2012. INDOT reminds drivers to use caution and consider worker safety when driving through a construction zone. For the latest news and information about INDOT, please visit www.in.gov/indot<http://www.in.gov/indot> or www.trafficwise.IN.gov<http://www.trafficwise.IN.gov>. ________________ Sidewalk Closure on North Side of Cary Begins Monday Work will be done on the gutters at Cary Northeast and Cary Northwest from Monday, November 7 through Monday, November 21. Man lifts will be utilized during this project, and the sidewalk will be closed on the north side of Cary along Tower Dr and on the inside of the courtyard. For questions, please contact Jack Johnson at 4-4889.

1 0

Abstract & Bio for Dr. William D. Young -- Venture Partner, Clarus Ventures, LLC
by Heide, Karen Kay 03 Nov '11

03 Nov '11

Dear All, The Abstract & Bio are listed below. Karen Mrs. Karen Heide, Secretary School of Chemical Engineering Purdue University Forney Hall of Chemical Engineering 480 Stadium Mall Drive West Lafayette IN 47907-2100 765-494-4050 765-494-0805 (Fax) Purdue University School of Chemical Engineering Graduate Seminar Series - Centennial Seminar Dr. William D. Young Venture Partner Clarus Ventures, LLC "History and Promise of Biotechnology" November 10, 2011 3:30 - 4:30 p.m. FRNY G140 Abstract: Dr. Young has worked and continues to work in the biotech industry since graduation from Purdue. He will describe the current environment for innovation in drug development and the challenges successfully faced in biotech process development and manufacturing in his 20 year career at Genentech. In addition to Genentech he will touch on biotech companies that he has helped to develop including Biogen IDEC, BioMarin, Theravance, and molecular diagnostic company Nanostring technologies including comments about the promise of personalized medicine. Bio: Mr. Young joined Clarus in 2010 as a Venture Partner from Monogram Biosciences, a leader in personalized medicine, where he served as Chief Executive Officer from 1999 through to the sale of the company to LabCorp in 2009. Mr. Young currently serves as Chairman of the Board of Directors of Biogen IDEC, Inc. and is a member of the board at Theravance, Inc. Mr. Young is also Executive Chairman of NanoString, a Clarus Ventures portfolio company focused on instrumentation and molecular diagnostics. Prior toE Monogram he was at Genenetch since 1980 at positions of increasing responsibility, including Chief Operating Officer responsible for all of the biotechnology company's development, operations and commercial functions. Prior to Genentech Mr. Young was at Eli Lilly and Company for fourteen years. Mr. Young received his bachelor's degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology.

1 0

2011 Safety Audit and Inspection Follow-up
by Davis, Linda S 01 Nov '11

01 Nov '11

ChE Faculty, Research Staff and Graduate Students, Our commitment to safety is ongoing. The attached document summarizes the most frequent safety issues and violations that were observed in our 2011 self audits and inspections. The issues fall into the categories of: safety documentation, PPE, chemicals, gas cylinders, lasers, gas detectors, facilities and emergency preparedness. Required actions or updates are also provided. We ask that each research group review, discuss and follow-up on the identified safety issues that apply in their laboratories. Please contact any of the ChE Safety Committee members for assistance. Thank you. Linda Linda S. Davis Industrial Education Director School of Chemical Engineering Purdue University lsdavis(a)purdue.edu<mailto:lsdavis@purdue.edu> (765)496-1710

1 0

GSO Seminar Announcement - November 1, 2011
by Ewing, Virginia G 01 Nov '11

01 Nov '11

Reminder: Seminar today. Students and faculty are invited to meet with Dr. Panitch from 1:30-2:30 pm in room 3059. Purdue University School of Chemical Engineering Graduate Seminar Series - GSO Seminar Dr. Alyssa Panitch Associate Department Head and Professor of Biomedical Engineering Purdue University "Tissue Healing and Regeneration: From Invention to Translation" Tuesday, November 1, 2011 3:30 - 4:30 p.m. FRNY G140 ABSTRACT: Using biology as a template for designing engineered analogues, we have developed two classes of molecular therapeutics coined peptidoglycans. The first class of molecules, called collagen-binding peptidoglycans, mimic many of the key functions of native small leucine-rich proteoglycans such as decorin. Proteoglycans are key ingredients for proper function and organization of collagenous tissues - the most abundant of thebody. The peptidoglycan design simplifies the native molecules to a polysaccharide chain with covalently attached collagen-binding peptides, but has the advantage of design control and the ability to make synthetically in large quantities. We have tailored the peptidoglycans for applications in dermal healing and inhibition of intimal hyperplasia following balloon angioplasty. The second class of peptidoglycans comprises mimics of the proteoglycan aggrecan. These mimics were designed based on the umet medical need of a treatment for osteoarthritis. The following design constraints were adapted: the aggrecan mimic must be resistant to proteolysis, easy to synthesis and must protect the native extracellular matrix from further degradation. Through out development of these technologies, the laboratory keeps a keen focus on both answering basic science and engineering questions and driving the technological solutions toward the market. This talk will focus both on research and technology transfer.

1 0